INTRODUCTION
Colon cancer was reported as the third most prevalent in the world with 940,000 new cases and 500,000 deaths each year [1, 2] . It was reported that 142,570 men and women were diagnosed with colorectal cancer (CRC) and 57,000 men and women died in 2010 in US [3, 4] . In Japan, colorectal cancer is the third leading cause of cancer death with 40,000 death per year [5, 6] . In Turkey, incidence of cancer is 173,85 per 100,000, 7,1 % of whom are diagnosed to have developed colon cancer [7] . In addition to prevalence and great mortality numbers metastases will develop in 30-40% of CRC patients [8] . This metastasis rate can also cause mortality. In the light of these, it could be said that metastases will Farmeconomia. Health economics and therapeutic pathways 2013; 14 (1) Treatment cost of metastatic colon cancer in Turkey semi synthetic inhibitor of topoisomerase, and oxaliplatin, a third-generation platinum compound, were developed as salvage therapies for patients failing 5-FU [10, 13, 14] and are treatment options for first-line, second-line and sequential treatment in colorectal cancer [10] . Many patients are now treated with sequential therapy resulting in prolonged overall survival to over 20 months [10, 15] .
However, the cost associated with this improved survival may be very high, even in the United States [16] . Although [17]. Although, there are studies for calculating cost of specific cancer treatments (breast cancer, lung cancer) in Turkey [18, 19] , there is not any published analysis for calculating cost of colon cancer. The aim of our study is to calculate the cost of colon cancer treatment protocols and cost per year with different combinations of protocols for Turkey using survival data calculated from a previously published Markov Model [16] .
METHODS
Gazi University Hospital, which is the one of third treatment hospitals in Ankara, Turkey, treatment protocols for colon cancer treatment were used. Cost of FUFA (5 FU/LV), FOLFI-RI, FOLFOX, bevacizumab/FUFA, bevacizumab/FOLFIRI, bevacizumab/FOLFOX, irinotecan and irinotekan/cetixumab protocols were calculated (Table I and Table II ). The costs were based upon average government reimbursement sales prices for a 70 kg patient with body surface area of 1.7 m 2 . Only drug and hospital base applications costs, like physician visit, intravenous drug infusion, etc, were included. The cost of pharmaceuticals and medical treatment used in the protocols were taken from the Social Security Institution's web site [20] (http://www.sgk. gov.tr) (Table III and Table IV ). The cost of best supportive care was excluded. Wong et al. developed a Markov model to estimate the cost effectiveness of up to three lines of therapy for metastatic colorectalcancer [16] . In this model, patients received one, two or three lines of therapy. In this model the "base case" scenario was single agent 5FU. We used the estimated time on each line of therapy to populate this model. The median period of each protocol administered in combinations and life expectancy data were taken from the published analysis. Cost of combination of protocols were calculated depending of these. Only cost of drugs were used for the calculations as in Wong`s study [16] . The analysis was conducted in the perspective of a third-party payer like the Turkish Social Security Institution which covers the 85% of the population. The exchange rate was US$ 1 for TL 1.5. Incremental cost effectiveness ratio (ICER) was calculated for each treatment. Life expectancy was calculated to years from weeks for ICER. The threshold for ICER was taken from WHO [21] .
RESULTS
The lowest cost for one cycle/month was established by FUFA (US$ 342). It was fol-A USA study [22] There is no set definition of cost-effective and this may vary from country to country. The World Health Organization noted that if the ICER is lower than gross domestic product per capita (GDPC) or between 1-3 x GDPC or higher than 3 x GDPC, it is very cost-effective, cost-effective or not cost-effective, respectively [21] . In this report the cost-effectiveness threshold is US$ 9,972 for Turkey region, which is consistent with the GDP of US$ 10,000 per year. The cost-effectiveness can be considered from US$ 9,972 to US$ 29,915 for each life year gained or quality adjusted life year. The other combinations of protocols were above the cost-effectiveness curve depending on life expectancy. In addition no treatments ICER was under the WHO's threshold for Turkey, except FOLFIRI then FOLFOX compared with FUVA. It is possible that if a formal cost-utility analysis was performed in Turkey, it would be very difficult to justify the current prices of pharmaceuticals and almost all high priced pharmaceuticals would not demonstrate enough value to be reimbursed like oncology, orphan, etc. On the other hand, cost-utility analysis would be of more use to demonstrate the value of oncology medicines. Even then, oncology medicines are being reimbursed in Turkey whether they can or cannot demonstrate value using cost-effectiveness analysis because it would not be acceptable if there were news in media such that some oncology patients died due to the fact that government did not reimburse oncology medicines. Because there is also a traditional way of thinking in Turkey, such as when (Table VI) .
On the other hand, if we calculate the average weighted curve for metastatic colon cancer treatment`s cost compared with life expectancy, FOLFOX, FOLFOX/ bevacizumab then irinotecan, FOLFIRI then FOLFOX, FOLFOX/bevacizumab then irinotecan then cetuximab are above the curve. The other combinations are below the curve (Figure 1 ).
DISCUSSION AND CONCLUSIONS
It has been estimated that there will be 8-9,000 new colon cancer patients every year in Turkey, and metastatic colon cancer will be developed in 2-3,000 of them. Due the high prevalence and cost of treatment of metastatic colon cancer, there may be a huge budget impact to Turkish health system. Turkish reimbursement decisions are given by the commissions in Social Security Institution (SGK). After Ministry of Health`s approve the license of pharmaceuticals, all pharmaceuticals needs to make application to SGK for reimbursement. However, they need to show their cost-effectiveness against to available treatment options in the market, most of companies perform analysis depending on their Phase III study in which mostly placebo used for comparing. However, although companies perform analysis for reimbursement application, few analyses is published in journals, congress, etc. There is not any published pharmacoeconomic analysis for the colon cancer treatment in Turkey. This analysis is the first for the literature. Our analysis have some limitations. Treatment protocols are dependent on only one University Hospital. Using the treatment protocols from different centers may lead to more accurate calculations for Turkey. Life expectancy Markov were calculated before KRAS testing which was used to identify patients who would respond to cetuximab. Due this the life expectancy will be different now for the predicting patients who may respond. This is the major limitation for the analysis. It is needed to run a new Markov with KRAS testing. In addition, discount rate was excluded from the analysis. Because there will be a discount in Turkish price, exchange rate TL/ US may change in years. it is a health issue, it is not well accepted by public to talk about costs and money, as maintaining health should be more important than money. So, nearly all oncology treatments are covered by reimbursement by the Social Security Institution. It can be said that it is hard to change the reimbursement decision about this disease due to the low survival rate of colon cancer and social
